Select Publications
Journal articles
2017, 'Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization', Clinical Trials, 14, pp. 264 - 276, http://dx.doi.org/10.1177/1740774517697919
,2017, 'Managing two decades of visceral leishmaniasis and HIV co-infection: A case report that illustrates the urgent research needs in the field', Sexual Health, 14, pp. 286 - 288, http://dx.doi.org/10.1071/SH16036
,2016, 'Tuberculosis screening in patients with HIV: An audit against UK national guidelines to assess current practice and the effectiveness of an electronic tuberculosis-screening prompt', International Journal of STD and AIDS, 27, pp. 901 - 905, http://dx.doi.org/10.1177/0956462416628355
,2016, 'Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first Nucleoside/Nucleotide reverse transcriptase inhibitor plus ritonavir-boosted protease inhibitor regimen: Week 48 Results of the randomized, multicenter March study', Clinical Infectious Diseases, 63, pp. 122 - 132, http://dx.doi.org/10.1093/cid/ciw207
,2016, 'Genotype 4 and the global challenge of hepatitis C treatment', The Lancet Gastroenterology and Hepatology, 1, pp. 3 - 4, http://dx.doi.org/10.1016/S2468-1253(16)30006-1
,2016, 'Evaluation of the Performance Properties of the Influenza Patient-Reported Outcomes Instrument (Flu-Pro)', Value in Health, 19, pp. A220 - A221, http://dx.doi.org/10.1016/j.jval.2016.03.1186
,, 2016, 'Oral abstracts of the 21st International AIDS Conference 18-22 July 2016, Durban, South Africa.', J Int AIDS Soc, 19, pp. 21264, http://dx.doi.org/10.7448/IAS.19.6.21264
2015, 'Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study', PLoS ONE, 10, pp. e0139981, http://dx.doi.org/10.1371/journal.pone.0139981
,2015, 'Factors Associated with Plasma IL-6 Levels during HIV Infection', Journal of Infectious Diseases, 212, pp. 585 - 595, http://dx.doi.org/10.1093/infdis/jiv123
,2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5
,2015, 'Why START? Reflections that led to the conduct of this large long-term strategic HIV trial', HIV Medicine, 16, pp. 1 - 9, http://dx.doi.org/10.1111/hiv.12227
,2015, 'Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study', PLoS Medicine, 12, pp. e1001809, http://dx.doi.org/10.1371/journal.pmed.1001809
,2015, 'Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy', Journal of Infectious Diseases, 211, pp. 529 - 538, http://dx.doi.org/10.1093/infdis/jiu486
,2015, 'Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.', HIV Med, 16 Suppl 1, pp. 109 - 118, http://dx.doi.org/10.1111/hiv.12239
,2014, 'Chagas disease in Australia and New Zealand: Risks and needs for public health interventions', Tropical Medicine and International Health, 19, pp. 212 - 218, http://dx.doi.org/10.1111/tmi.12235
,2014, 'Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial', The Lancet, 383, pp. 1474 - 1482, http://dx.doi.org/10.1016/S0140-6736(13)62187-X
,2014, 'Human antigen-specific CD4+CD25+CD134+CD39+ T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses', European Journal of Immunology, 44, pp. 1644 - 1661, http://dx.doi.org/10.1002/eji.201344102
,2014, 'Identifying chagas disease in Australia: An emerging challenge for general practitioners', Australian Family Physician, 43, pp. 440 - 442
,2014, 'Incomplete restoration of Mycobacterium tuberculosis-specific-CD4 T cell responses despite antiretroviral therapy', Journal of Infection, 68, pp. 344 - 354, http://dx.doi.org/10.1016/j.jinf.2013.11.016
,2014, 'Ratios of effector to central memory antigen-specific CD4 + T cells vary with antigen exposure in HIV+ patients', Immunology and Cell Biology, 92, pp. 384 - 388, http://dx.doi.org/10.1038/icb.2013.101
,2014, 'Determinants of IL-6 levels during HIV infection.', J Int AIDS Soc, 17, pp. 19482, http://dx.doi.org/10.7448/IAS.17.4.19482
,2013, 'Restoration of CMV-Specific-CD4 T Cells with ART Occurs Early and Is Greater in Those with More Advanced Immunodeficiency', PLoS ONE, 8, http://dx.doi.org/10.1371/journal.pone.0077479
,2013, 'Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc switch collaborative study', Journal of Clinical Microbiology, 51, pp. 2063 - 2071, http://dx.doi.org/10.1128/JCM.00510-13
,2013, 'Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study', PLoS ONE, 8, pp. e56249, http://dx.doi.org/10.1371/journal.pone.0056249
,2013, 'Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 62, pp. 525 - 533, http://dx.doi.org/10.1097/QAI.0b013e3182832578
,2013, 'The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies', PLoS ONE, 8, pp. e57121, http://dx.doi.org/10.1371/journal.pone.0057121
,2012, 'A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison with existing assays', Tuberculosis, 92, pp. 321 - 327, http://dx.doi.org/10.1016/j.tube.2012.03.008
,2012, 'A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 60, pp. 143 - 149, http://dx.doi.org/10.1097/QAI.0b013e318252f97e
,2012, 'Anal cytological abnormalities are poor predictors of high-grade intraepithelial neoplasia amongst HIV-positive men who have sex with men.', Sexual Health, 10, pp. 9 - 17, http://dx.doi.org/10.1071/SH11135
,2012, 'Clinical studies with chemokine receptor-5 (CCR5)-inhibitors', Current opinion in HIV & AIDS, 7, pp. 456 - 462, http://dx.doi.org/10.1097/COH.0b013e328356e933
,2012, 'Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study', CLINICAL TRIALS, pp. 1 - 32, http://dx.doi.org/10.1177/1740774512440342
,2011, 'Enfuvirtide injection site reactions: A clinical and histopathological appraisal', Australasian Journal of Dermatology, 52, pp. 19 - 26, http://dx.doi.org/10.1111/j.1440-0960.2010.00717.x
,2011, 'Participants' perspectives of high resolution anoscopy', Sexual Health, 8, pp. 255 - 256, http://search.informit.com.au/documentSummary;dn=026919938891985;res=IELHEA
,2011, 'Participants' perspectives of self-collected anal cytological swabs', Sexual Health, 8, pp. 257 - 258, http://search.informit.com.au/documentSummary;dn=026957204834502;res=IELHEA
,2011, 'Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)', HIV Medicine, 12, pp. 219 - 227, http://dx.doi.org/10.1111/j.1468-1293.2010.00875.x
,2011, 'Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site netwok approach: The INSIGHT FLU 002 and FLU 003 studies', Vaccine, 29, pp. B56 - B62
,2010, 'A novel Chemokine-Receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection', AIDS Research and Human Retroviruses, 26, pp. 653 - 661, http://dx.doi.org/10.1089/aid.2009.0278
,2010, 'Antiretroviral agents: Focus on maraviroc for the treatment of HIV-1-infected adults', Clinical Medicine Insights: Therapeutics, 2, pp. 697 - 713, http://www.la-press.com/
,2010, 'Antiretroviral agents: Focus on Maraviroc for the Treatment of HIV-1-Infected Adults', Clinical Medicine Insights: Therapeutics, 2, pp. CMT.S5420 - CMT.S5420, http://dx.doi.org/10.4137/cmt.s5420
,2010, 'Markers of inflammation, coagulation and renal function are elevated in adults with HIV infection', Journal of Infectious Diseases, 201, pp. 1788 - 1795
,2010, 'Role of interleukin-2 inpatients with HIV infection', Drugs, 70, pp. 1115 - 1130
,2009, 'A Phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients', Antiviral Therapy, 14, pp. 111 - 115
,2009, 'High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40)', Journal of Immunology, 183, pp. 2827 - 2836, http://dx.doi.org/10.4049/jimmunol.0803548
,2009, 'Immunotherapies in HIV-1 infection', Current opinion in HIV & AIDS, 4, pp. 188 - 193
,2009, 'Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease', European Journal of Immunology, 39, pp. 391 - 403, http://dx.doi.org/10.1002/eji.200838630
,2008, 'Changes in CCR5+ cells and antigen-specific CD4+ T-cells during monotherapy with a CCR5 antagonist SCH532706 compared with combination therapy', Journal of the International AIDS Society, 11, http://dx.doi.org/10.1186/1758-2652-11-s1-p297
,2008, 'Experimental and clinical pharmacology - HIV fusion inhibitors: a review', Australian Prescriber, 31, pp. 66 - 69
,2007, 'Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples', Clinical and Vaccine Immunology, 14, pp. 52 - 59
,2006, 'Evaluation of Subcutaneous Proleukin (Interleukin-2) in a Randomized International Trial (ESPRIT): Geographical and Gender Differences in the Baseline Characteristics of Participants', HIV Research & Clinical Practice, 7, pp. 70 - 85, http://dx.doi.org/10.1310/hct.2006.7.2.005
,2006, 'Evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants', HIV Clinical Trials, 7, pp. 70 - 85
,